Stocks · News reference
If You Invested $100 In Cytokinetics Stock 10 Years Ago, You Would Have This Much Today
Cytokinetics (NASDAQ:CYTK) has outperformed the market over the past 10 years by 7.78% on an annualized basis producing an average annual return of 21.28%. Currently, Cytokinetics has a market capitalization of $10.34
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 28, 2026, 4:30 PM
- Checked
- Aug 28, 2026, 4:30 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
8-K filing — CYTOKINETICS INC (CYTK)
Filed: 2026-08-28 AccNo: 0001193125-26-372456 Size: 1 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read original at edgarCytokinetics Announced The Primary Results From ACACIA-HCM (Assessment Comparing Aficamten To Placebo On Cardiac Endpoints In Adults With Non-obstructive HCM), The Pivotal Phase 3 Clinical Trial Of Aficamten In Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
Read original at benzingaCytokinetics Announces Primary Results From Phase 3 Trial Of Aficamten In Non-Obstructive Hypertrophic Cardiomyopathy To Be Presented August 28 At ESC Congress
Read original at benzinga